Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walgreens set to Take Care

This article was originally published in The Tan Sheet

Executive Summary

Walgreens acquires leading convenient care clinic firm Take Care Health Systems for an undisclosed amount and the new acquisition will operate as a wholly-owned subsidiary of the national retailer, Walgreens announces May 24. Take Care's 51 health care clinics in Chicago, Kansas City, Milwaukee, St. Louis and Pittsburgh will be combined with the drugstore chain's approximately 5,700 pharmacies nationwide setting the stage for future rollout of a variety of patient-focused health care services. "This is going to allow us to offer a suite of health care services going forward being offered by the clinics and the pharmacies," Walgreens told "The Tan Sheet." The companies have aligned key priorities to focus on a national rollout of convenient care clinics and more than 400 clinics are planned by the end of 2008. "Walgreens shares in our mission to provide a health care solution for all individuals, and we are proud to formally join the Walgreens family today," Take Care President and CEO Peter Miller said...

You may also be interested in...



EU Firsts Beckon For Olumiant In Dermatitis & Orfadin For AKU

The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.

Roche Bulks Up In NLRP3 With €380m Inflazome Buy

Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.

Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia

Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel